BioMarin Pharmaceutical Inc. announced that effective January 29, 2020, Dan Spiegelman had transitioned from serving as the Companys Executive Vice President and Chief Financial Officer. Mr. Spiegelman will remain with BioMarin as an employee and senior advisor until September 1, 2020 (the Separation Date) to assist with the transition. After that, he plans to pursue other interests and spend more time with family. Also on January 29, 2020, Brian Mueller, BioMarins Senior Vice President, Finance and Chief Accounting Officer assumed the roles of acting Chief Financial Officer and principal financial officer, in addition to his responsibilities as principal accounting officer, while the Company conducts an internal and external search for the role of Chief Financial Officer. Mr. Mueller joined BioMarin in December 2002 and currently serves as the Companys Senior Vice President, Finance and Chief Accounting Officer in addition to his role as acting Chief Financial Officer. He has served as BioMarins Chief Accounting Officer since March 2011. From March 2014 to August 2016, Mr. Mueller served as the Companys Group Vice President, Corporate Controller and from March 2009 to March 2014, Mr. Mueller served as the Companys Vice President, Corporate Controller. Mr. Mueller is a member of the board of Directors of Anthera Pharmaceuticals Inc., a biopharmaceutical company where he also served as Chairman of the Audit Committee. Prior to joining BioMarin in 2002, Mr. Mueller worked for KPMG as a senior manager in the firms audit practice. Mr. Mueller joined KPMG after Arthur Andersen LLP ceased operations in June 2002, prior to which he spent seven years with Arthur Andersen LLP in the firms audit and business advisory services practice.